Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

14.01 -0.17 (-1.20%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

October 15, 2025

From Summit Therapeutics

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

1 Monster Stock in the Making to Buy and Hold ↗

October 05, 2025

This biotech company was relatively unknown a few years ago.

Via The Motley Fool

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence ↗

October 01, 2025

Via Benzinga

Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’ ↗

September 16, 2025

Via Stocktwits

Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains ↗

September 07, 2025

Via Stocktwits

Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio? ↗

September 28, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 24, 2025

From Pomerantz LLP

Via GlobeNewswire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 24, 2025

From Summit Therapeutics

Via Business Wire

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

September 24, 2025

From Summit Therapeutics

Via Business Wire

Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends ↗

September 23, 2025

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly...

Via Benzinga

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 17, 2025

Via Benzinga

Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock ↗

September 15, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a meme stock."

Via Benzinga

Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio? ↗

September 14, 2025

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.

Via Benzinga

Topics Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Top 3 Health Care Stocks You'll Regret Missing In Q3 ↗

September 09, 2025

Via Benzinga

Is Summit Therapeutics a Buy, Sell, or Hold Now? ↗

September 09, 2025

Western results for ivonescimab aren't lining up with the huge survival benefit measured in China.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

Gold Moves Higher; Robinhood Shares Jump ↗

September 08, 2025

Via Benzinga

Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗

September 08, 2025

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

Via Investor's Business Daily

Top movers in Monday's pre-market session ↗

September 08, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences ↗

September 08, 2025

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.

Via Benzinga

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

September 08, 2025

Via Benzinga

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

September 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3 ↗

September 04, 2025

The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.

Via Stocktwits

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

September 03, 2025

From Summit Therapeutics

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.